physiology of growth hormone secretion W7 Flashcards

1
Q

name for cells which secrete growth hormone?

A

somatotrophs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

where are somatotrophs found?

A

somatotrophs are found in the anterior pituitary (comprise 35-45%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

name of disorder of excess GH production

A

acromegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

growth hormone axis?

A

hypothalamus releases GHRH, acts on pituitary which releases GH. GH predominantly acts on the liver, stimulates release of IGF-1.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

IGF-1 stands for?

A

insulin-like growth factor 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

key inhibitory factor? where is this released?

A

SRIF (somatostatin) released from hypothalamus
also known as GHIH (growth hormone inhibiting hormone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

which area of the hypothalamus is growth hormone released from

A

preoptic area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

GHRH receptors pathway?

A

G protein coupled receptor. increases adenylate cyclase which increases cAMP which increases intracellular calcium, causing release of growth hormone and increase in growth hormone mRNA transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is GHRH receptors enhanced by

A

oestradiol
ghrelin
glucocorticoids
starvation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is GHRH receptors blunted by

A

somatostatin
obesity
insulin
glucose
increased age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ghrelin features

A

orexigenic (enhances food consumption)
produced in stomach (particularly in fasting and pre-meal state)
enhances GH secretion
maintains blood glucose levels during starvation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

somatostatin features

A

released from PVN of hypothalamus
peptide hormone
acts on 5 different G-protein coupled receptors
suppressive effect on multiple pituitary hormones (including GH and TSH) and insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

where is growth hormone receptor most dominantly expressed

A

liver!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

GHR intracellular signalling type? what does it stimulate?

A

phosphorylation cascade
hepatic IGF-1 synthesis and secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IGF-1 features?

A

responsible for most linear growth-promoting activities of GH
99% is protein bound
mainly produced in liver
IGF-1 receptor present across multiple tissues
ligand binding -> TK activity -> IRS-1 pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

physiologic stimulatory factors for GH

A

exercise
stress
physical
psychologic
slow-wave sleep
fasting

17
Q

physiologic inhibitory factors for GH

A

hyperglycaemia
elevated free fatty acids
elevated IGF-1
REM sleep
senescence, aging

18
Q

pathological stimulatory factors for GH

A

renal failure
cirrhosis
type 1 diabetes

19
Q

pathological inhibitory factors for GH

A

obesity
hypothyroidism
hyperthyroidism

20
Q

pattern of GH secretion?

A

pulsatile - reductions in tonic inhibition by somatostatin
diurnal - 2/3 secreted at night with onset at slow wave sleep
peaks at puberty, falls with ageing

21
Q

growth hormone actions?

A

direct and indirect (via IGF-1) action on epiphyseal growth plates to stimulate linear growth
increases lipolysis and lipid oxidation (mobilization of stored TG)
stimulates protein synthesis
antagonism of insulin action
phosphate, water and sodium retention

22
Q

IGF-1 actions?

A

decrease blood glucose/improve insulin sensitivity
stimulate whole body protein synthesis, inhibit proteolysis
reverse catabolic effects of glucocorticoids on protein synthesis
anabolic effect on bone
negative feedback on GH release

23
Q

laron syndrome?

A

mutations in GHR
normal/high GH, low GH-binding protein, low IGF-1
postnatal growth failure
small head circumference, saddle nose, prominent forehead, delayed skeletal maturation, osteopenia and obesity
reduced cancer susceptibility

24
Q

GH deficiency in children?

A

severe growth failure
treat with recombinant growth hormone when epiphyses are open
monitor IGF-1 levels during treatment, continue until linear growth complete then retest for GH deficiency

25
Q

GH deficiency in adults - diagnostic tests?

A

IGF-1 lower than reference range confirms diagnosis in adults with pituitary disease
stimulatory tests (GHRH-arginine)

26
Q

GH replacement in adults is associated with what?

A

increased muscle mass, decreased body fat, increased exercise capacity, increased bone mineral density in men, increase in some parameters of cardiac function

27
Q

is GH replacement recommended in adult onset GH deficiency?

A

GHR recommended against because evidence not strong and potential adverse consequences often outweigh potential benefits

28
Q

acromegaly features?

A

delay from symptoms to diagnosis is 12 years (very rare condition)
75% due to somatotroph macroadenomas in pituitary

29
Q

macroadenoma?

A

tumour greater than 1cm

30
Q

acromegaly presentation?

A

headache
enlargement of lips, nose, tongue
cardiomyopathy
CVD
prognathism (growth of lower jaw)
increased sweating
thicker skin
hypertension
enlargement of liver
type 2 diabetes risk
colon cancer risk
enlargement of hands
carpal tunnel syndrome
myopathy
arthropathy
enlargement of feet

31
Q

acromegaly diagnosis?

A

test in those with classical clinical features, clusters of associated features, and those with pituitary adenoma

measure IGF-1, if equivocal do oral glucose tolerance test, if elevated then acromegaly is confirmed in patients with clinical manifestations, if normal then rule out acromegaly

32
Q

acromegaly treatment?

A

pituitary surgery (removal of adenoma) as first line
somatostatin analogues to inhibit GH release (lanreotide)
GHR antagonist (pegvisomant)
pituitary radiotherapy